Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments

New findings from a landmark clinical trial show that although certain gene variants may predict whether a person will develop age-related macular degeneration (AMD), these genes do not predict patients’ responses to Lucentis™ and Avastin™, two medications widely used to treat «wet» AMD. This genetics study is based on the landmark CATT study data and is published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

Fuente : http://www.eurekalert.org/pub_releases/2013-02/aao…


Hacer un comentario